英文論文
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
2015
Tanaka Y, Aoyagi K, Minashi K, Komatsuzaki R, Komatsu M, Chiwaki F, Tamaoki M, Nishimura T, Takahashi N, Oda I, Tachimori Y, Arao T, Nishio K, Kitano S, Narumi K, Aoki K, Fujii S, Ochiai A, Yoshida T, Muto M, Yamada Y, Sasaki H.
Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy.
PLoS One. 2015 Dec 1;10(12):e0143804.
Shinya Ohashi, Shin’ichi Miyamoto, Osamu Kikuchi, Tomoyuki Goto, Yusuke Amanuma, and Manabu Muto.
Recent Advances from Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma.
Gastroenterology 2015 Dec;149(7):1700-15.
Horimatsu T, Miyamoto S, Mashimo Y, Okabe H, Mikami Y, Chiba T, Muto M.
Pseudo-Meigs’ Syndrome Caused by a Krukenberg Tumour of Gastric Cancer.
Intern Med. 2015;54(20):2595-7.
Setoyama T, Miyamoto S, Nikaido M, Muto M, Chiba T.
Instability of IGF-IGFBP complex as a cause of the different performance of serum and EDTA-plasma after storage: EDTA-plasma is preferable for evaluating bioactive IGF especially in the mouse.
Growth Horm IGF Res. 2015 Oct;25(5):227-31.
Yusuke Amanuma, Shinya Ohashi, Yoshiro Itatani, Mihoko Tsurumaki, Shun Matsuda, Osamu Kikuchi, Yukie Nakai, Shin’ichi Miyamoto, Tsunehiro Oyama, Toshihiro Kawamoto, Kelly Whelan, Hiroshi Nakagawa, Tsutomu Chiba, Tomonari Matsuda, and Manabu Muto.
Protective role of ALDH2 against acetaldehyde-derived DNA damage in oesophageal squamous epithelium.
Scientific Reports 2015 Sep 16;5:14142.
Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Makato Y, Higurashi T, Yukawa N, Amanuma Y, Kikuchi O, Muto M, Ueno Y, Nakajima A, Chiba T, Boland CR, Goel A.
Serum miR-21, miR-29a and miR-125b are promising biomarkers for the early detection of colorectal neoplasia.
Clin Cancer Res. 2015 Sep 15;21(18):4234-42.
Sato F, Kubota Y, Natsuizaka M, Maehara O, Hatanaka Y, Marukawa K, Terashita K, Suda G, Ohnishi S, Shimizu Y, Komatsu Y, Ohashi S, Kagawa S, Kimugasa H, Whelan KA, Nakagawa H, Sakamoto N.
EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Cancer Biol Ther. 2015, 16(6) : 933-40
Fujiwara Y, Kobayashi S, Nagano H, Kanai M, Hatano E, Toyoda M, Ajiki T, Takashima Y, Yoshimura K, Hamada A, Minami H, Ioka T.
Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).
PLoS One. 2015 Dec 3;10(12):e0143072.
Kishi T, Nakamura A, Itasaka S, Shibuya K, Matsumoto S, Kanai M, Kodama Y, Takaori K, Mizowaki T, Hiraoka M.
Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer.
Pancreatology. 2015 Nov-Dec;15(6):694-700
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I.
Safety and anti-tumor activity of anti-PD-1 antibody (nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.
J Clin Oncol. 2015 Dec 1;33(34):4015-22.